ChemoCentryx, Inc.

États‑Unis d’Amérique


Commandez votre montre hebdomadaire ChemoCentryx, Inc.
Quantité totale PI 378
Rang # Quantité totale PI 3 488
Note d'activité PI 3/5.0    130
Rang # Activité PI 5 196
Symbole boursier CCXI (nasdaq)
ISIN US16383L1061
Capitalisation 4,000M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

199 5
80 4
79 2
9
 
Dernier brevet 2025 - Heteroaryl-biphenyl amines for t...
Premier brevet 2000 - Compounds and methods for modula...
Dernière marque 2020 - TAVYLBY
Première marque 2002 - CHEMOCENTRYX

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases. Compounds are provided that are ...
2024 Invention Methods of treating cancer using heteroaryl-biphenyl amide derivatives. Provided herein are meth...
Invention Cxcr7 inhibitors for the treatment of cancer. Provided herein are methods of treating cancer in ...
Invention Capsule formulations. The present disclosure provides solid solution capsule formulations of Com...
Invention Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor. T...
2023 Invention Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il...
Invention Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases. Compounds are provided that are ...
Invention Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibi...
Invention Free base crystalline form of a complement component c5a receptor. Provided herein is a free bas...
Invention Ccr4 antagonists. Compounds are provided having formula (I): Compounds are provided having for...
Invention Ccr4 antagonists. Compounds are provided having formula (I) wherein the groups/letters R1a, R1b, ...
Invention Cxcr6 sulfonamide compounds. Provided are sulfonamide compounds having formula (I): Provided a...
Invention Cxcr6 sulfonamide compounds. Provided are sulfonamide compounds having formula (I) or a pharmaceu...
2022 Invention C5ar antagonists. Compounds are provided that are modulators of the C5a receptor. The compounds ...
Invention Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors. The present disclosure provides, ...
Invention Aryl sulfonyl compounds as ccr6 inhibitors. Compounds of formula (I) are provided which are usefu...
Invention Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors. Compounds of formula (A) are provided whi...
Invention Combination therapy using c—c chemokine receptor 4 (ccr4) antagonists and one or more immune chec...
Invention 2-oxindole compounds. Oxindole compounds useful for the treatment of CCR(9) mediated conditions o...
Invention C5ar inhibitor reduction of urinary scd163. Provided herein are methods of treating ANCA-associa...
Invention Immunomodulator compounds. Compounds are provided that are useful as immunomodulators. The compou...
Invention Treatment of focal segmental glomerulosclerosis with ccr2 antagonists. Provided herein are metho...
P/S Pharmaceutical products for the treatment of autoimmune and inflammatory diseases
Invention Method of treating liver fibrosis. A method of treating liver fibrosis with CCR2 antagonists is ...
Invention 6-5 fused rings as c5a inhibitors. The present disclosure provides, inter alia, Compounds of Form...
Invention Azetidinyl-acetamides as cxcr7 inhibitors. Compounds having formula I: (I), or pharmaceutically a...
Invention Method of treating focal segmental glomerulosclerosis. A method of treating focal segmental glome...
Invention Method of treating c3 glomerulopathy. aR antagonist are provided.
Invention Processes and intermediates in the preparation of c5ar antagonists. Intermediates and methods are...
Invention Triaryl compounds for treatment of pd-l1 diseases. Compounds are provided that are useful as imm...
2021 Invention Treatment of c3 glomerulopathy using a c5a inhibitor. Methods of treating certain human patient ...
Invention Treatment of c3 glomerulopathy using a c5a inhibitor. Methods of treating certain human patient p...
Invention Capsule formulations. The present disclosure provides solid solution capsule formulations of Comp...
Invention Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2. The prese...
Invention Dosing and effect of c5a antagonist with anca-associated vasculitis. The present disclosure provi...
Invention Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides. Compounds are provided that act as potent antagon...
Invention Methods of treating hidradenitis suppurativa. Provided herein are methods for treating a subject ...
Invention Methods of treating solid tumors with ccr2 antagonists. The present disclosure provides, inter a...
Invention Substituted anilines as ccr(4) antagonists. Aniline compounds are provided which bind to CCR(4) a...
Invention Indane-amines as pd-l1 antagonists. Compounds are provided that are useful as immunomodulators. T...
Invention Methods of treating respiratory diseases using c5a inhibitors. Provided herein are methods of tr...
Invention Substituted tetrahydropyrans as ccr2 modulators. Compounds are provided that are modulators of th...
Invention Macrocyclic immunomodulators. Compounds are provided that are useful as immunomodulators. The com...
Invention Cxcr7 antagonists. Compounds having formula I, or pharmaceutically acceptable salts, hydrates o...
2020 P/S Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory and a...
P/S Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory bowel...
2018 P/S Pharmaceutical products.
P/S Pharmaceutical preparations for the treatment of autoimmune diseases; anti-inflammatories, anti-i...
2009 P/S Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic ...
P/S Full line of pharmaceutical preparations.
P/S PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND A...
2006 P/S Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory and ...
P/S RESEARCH AND DEVELOPMENT FOR NEW PRODUCTS IN THE FIELD OF CHEMOKINES AND GENETIC MATERIALS FOR OT...
2004 P/S Pharmaceutical preparations for use in the treatment of human disease, including inflammatory and...
2002 P/S Cooperative advertising and marketing for pharmaceuticals and therapeutics; retail and wholesale ...